

2nd Quarter 2021 Results

2nd Quarter 2021 Sales

\$23.3B | Worldwide Increased \uparrow **27.1%** | Excluding acquisitions/divestitures on an operational basis | Worldwide Increased \uparrow **23.8%***

Diluted Earnings Per Share

\$2.35 | Increased \uparrow **72.8%**

Adjusted Diluted Earnings Per Share*

\$2.48 | Increased \uparrow **48.5%**



Alex Gorsky
Chairman and Chief Executive Officer
Johnson & Johnson

“Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses. I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders.”

\$3.7 Billion

Worldwide Consumer Health Sales


Consumer Health worldwide reported sales increased 13.3% or 9.2% operationally¹. Primary operational drivers:



\$12.6 Billion

Worldwide Pharmaceutical Sales


Pharmaceutical worldwide reported sales increased 17.2% or 13.6% operationally¹. Primary operational drivers:



\$7.0 Billion

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales increased 62.7% or 57.2% operationally¹. Primary operational drivers:



Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on July 21, 2021, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

¹Non-GAAP measure; excludes the impact of translational currency.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on July 21, 2021, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.